Results 11 to 20 of about 132,691 (210)

Computational modelling of cancerous mutations in the EGFR/ERK signalling pathway [PDF]

open access: yes, 2009
This article has been made available through the Brunel Open Access Publishing Fund - Copyright @ 2009 Orton et al.BACKGROUND: The Epidermal Growth Factor Receptor (EGFR) activated Extracellular-signal Regulated Kinase (ERK) pathway is a critical cell ...
Gormand, A   +27 more
core   +1 more source

Improved Biological Impacts of Anti-EGFR Monoclonal Antibody in KRAS-Mutant Colorectal Cancer Cells by Silica-Coated Magnetic Nanoparticle Conjugation [PDF]

open access: yesPharmaceutical Sciences
Background: The therapeutic potential of epidermal growth factor receptor (EGFR) targeting in colorectal cancer (CRC) is hindered by the presence of KRAS codon 12 activating mutations, prevalent in approximately 25% of advanced CRC cases.
Maedeh Yousefi   +4 more
doaj   +1 more source

Osimertinib – effective treatment of NSCLC with activating EGFR mutations after progression on EGFR tyrosine kinase inhibitors [PDF]

open access: yes, 2017
Non-small cell lung cancer (NSCLC) driven by activating mutations in epidermal growth factor receptor (EGFR) constitutes up to 10% of NSCLC cases. According to the NCCN recommendations, all patients (with the exception of smoking patients with squamous ...
Marcin Skrzypski   +2 more
core   +1 more source

Blockade of Radiation-induced EGFR Nuclear Transport Enhances Radiosensitivity of Human Cervical Cancer

open access: yesZhongliu Fangzhi Yanjiu, 2020
Objective To investigate whether the inhibition of EGFR nuclear transport could reduce the radioresistance of human cervical cancer cells. Methods Human cervical cancer CaSki and HeLa cells were exposed to radiation treated with or without Thr654 ...
LI Lu   +6 more
doaj   +1 more source

Canine parvovirus induces G1/S cell cycle arrest that involves EGFR Tyr1086 phosphorylation

open access: yesVirulence, 2020
Canine parvovirus (CPV) has been used in cancer control as a drug delivery vehicle or anti-tumor reagent due to its multiple natural advantages. However, potential host cell cycle arrest induced by virus infection may impose a big challenge to CPV ...
Xiaofeng Dai   +4 more
doaj   +1 more source

EGFR-Targeted Liposomes Combined with Ginsenoside Rh2 Inhibit Triple-Negative Breast Cancer Growth and Metastasis

open access: yes, 2023
Triple-negative breast cancer (TNBC) remains the most challenging breast cancer subtype due to its lack of targeted therapies and poor prognosis. In order to treat patients with these tumors, efforts have been made to explore feasible targets.
Aiguo Wu (315321)   +19 more
core   +1 more source

Epidermal growth factor receptor-mutated non-small-cell lung cancer: A primer on contemporary management

open access: yesCancer Research, Statistics, and Treatment, 2019
Non-small-cell lung cancer (NSCLC) constitutes 85% of patients diagnosed with lung cancer. In metastatic cases, its treatment classically consists of systemic cytotoxic chemotherapy, which resulted in a median overall survival of 7.9 months.
Akhil Rajendra   +5 more
doaj   +1 more source

Incomplete reversibility of eGFR following tenofovir exposure [PDF]

open access: yes, 2014
Background. Tenofovir disoproxil fumarate (TDF) has been linked to renal impairment but the extent to which this impairment is reversible is unclear. We aimed to investigate the reversibility of renal decline on TDF.Methods.
Lisa Hamzah   +55 more
core   +1 more source

Study of EGFR expression in tumor tissue in patients with locally advanced oral cavity cancer receiving cetuximab therapy

open access: yesМедицинский совет, 2020
Introduction: Squamous cell carcinoma of the oral cavity is one of the most common head and neck cancers with an aggressive course and high mortality rates.
A. A. Lyanova   +12 more
doaj   +1 more source

EGFR-Targeted Nanobody Functionalized Polymeric Micelles Loaded with mTHPC for Selective Photodynamic Therapy

open access: yes, 2020
meta-Tetra­(hydroxyphenyl)­chlorin (mTHPC) is one of the most potent second-generation photosensitizers, clinically used for photodynamic therapy (PDT) of head and neck squamous cell carcinomas.
Javier Sastre Toraño (1685377)   +19 more
core   +1 more source

Home - About - Disclaimer - Privacy